12.8 c
Sunday, December 10, 2023

New Immuno-Cell Therapy] Mitsubishi UFJ Capital additionally invests in Gaia Biomedicine, a developer of "other home NK-like cells.

Mitsubishi UFJ Capital has invested in Gaia Biomedicine, a developer of a new immuno-cell therapy, "in vitro natural killer-like cells," through a third-party allotment of new shares as the lead investor. Gaia Biomedicine raised a total of 1.3 billion yen in Series B funding.

About Gaia Biomedicine, Inc. and Developed Products

(Head Office: Shinjuku-ku, Tokyo; Representative Director: Kazuyuki Kuramori) is a Kyushu University venture company that is developing a new cancer immuno-cell therapy based on the research results of Professor Yoshikazu Yonemitsu of the Graduate School of Pharmaceutical Sciences, Kyushu University.
GAIA-102 is a genetically engineered T cell that has been developed to enhance the ability to attack cancer cells without genetic modification or transduction manipulation. GAIA-102 is expected to be a more promising cancer immuno-cell therapy for solid tumors than other cellular drugs such as CAR-T. GAIA-102 also has a competitive advantage in terms of commercial use because of its extremely simple manufacturing and dosing process compared to other cellular therapeutics.
A notification of clinical trial has already been submitted to the Pharmaceuticals and Medical Devices Agency (PMDA) and a 30-day investigation has been completed, and a Phase 1/2 clinical trial for non-small cell lung cancer will begin this year.

Investment Background

Mitsubishi UFJ Capital has been investing in GAIA Biomedicine as a lead investor since the Series A investment in January 2020. Recently, Gaia Biomedicine has completed the originally planned manufacturing process and non-clinical testing of GAIA-102, and has advanced to the stage where clinical trials can be conducted, and has therefore made an additional investment in Series B along with some existing shareholders. The funds raised will be used to confirm the safety and efficacy of GAIA-102 in patients with non-small cell lung cancer, a type of solid tumor that is difficult to treat with conventional cancer immuno-cell therapy, through Phase I/II clinical trials in humans for the first time. Mitsubishi UFJ Capital intends to continue to support Gaia Biomedicine's business growth by making full use of MUFG's network.

About Gaia Biomedicine Inc.

name of companyGaia Biomedicine Inc.
EstablishmentOctober 2015
Location1-8, Tsukudo-cho, Shinjuku-ku, Tokyo

(Joint Research Office)
Kyushu University Hospital Campus Collaboration Station II, 3-1-1 Umade, Higashi-ku, Fukuoka City, Fukuoka
representativeKazuyuki Kuramori
Business OverviewDevelopment of Cancer Immuno-Cell Therapy
uniform resouce locatorhttps://gaia-biomed.com

About Mitsubishi UFJ Capital Co.

Since its establishment in 1974, Mitsubishi UFJ Capital has invested in a wide range of industries, providing industry-leading expertise as the venture capital arm of Mitsubishi UFJ Financial Group. The company has a top-class track record in the industry, with approximately 900 IPOs across a wide range of industries.

In the life science field, after the establishment of the Life Science Office in 2009, we began providing funding and management support to bio ventures in Japan and overseas on a full-scale basis. In February 2019, Mitsubishi UFJ Life Science No. 2 Investment Limited Partnership (10 billion yen) was formed, and in June 2020, MUFG Medical Fund (10 billion yen) was formed to support venture companies involved in drug discovery, regenerative medicine, and other fields, including measures against new coronary infections. In June 2020, the company formed the MUFG Medical Fund (10 billion yen) to support venture companies involved in drug discovery, regenerative medicine, etc., including those fighting new coronary infections. In addition to bio-venture investments, the company is also focusing on academia drug discovery, pharmaceutical company carve-out deals, investments in pharmaceutical company development projects, and medical device-related investments.

name of companyMitsubishi UFJ Capital Co.
EstablishmentAugust 1, 1974
LocationNihonbashi Plaza Building 7F, 2-3-4 Nihonbashi, Chuo-ku, Tokyo
representativeShinsuke Sakamoto, President and Representative Director
Business OverviewVenture Capital Business
uniform resouce locatorhttps://www.mucap.co.jp/

About Mitsubishi UFJ Life Science No. 2 Investment Limited Partnership

Investment Target:
Focus on investment activities in pharmaceutical company-originated and domestic academia drug discovery
-Regenerative Medicine Products
-Medical devices, etc.
-Diagnostics and diagnostic equipment

Unlimited liability partner:Mitsubishi UFJ Capital Co.

Investors:The Bank of Mitsubishi UFJ, Ltd. and Mitsubishi UFJ Capital Co.

Date of establishment:February 20, 2019

Total Fund Amount:10 billion yen

Facebook Comments
PORT Editorial Officehttps://port.creww.me/
PORT by Creww is an open innovation media for startups, entrepreneurs, entrepreneurs in recovery, and companies seeking to create new businesses on the theme of social issues, operated by Creww Co.
- Advertisment -
- Advertisment -


Ando Hazama x Cube Earth] Innovating the world's urban OS with patented technology from Japan and the U.S.

Creww Growth Case Study Interview】Ando Hazama has selected Cube Earth, a startup company offering a "smart disaster prevention system" to local governments through the "Ando Hazama New Business Co-Creation Program 2022," an accelerator program for fiscal year 2022, utilizing Cube Earth, a geographic information system platform patented in the United States and Japan. Cube Earth, a startup company that provides municipalities with a "smart disaster prevention system" using the geographic information system platform "Cube Earth" patented in the U.S. and Japan, was selected for the Ando Hazama New Business Co-Creation Program 2022. The startup is developing next-generation social infrastructure infrastructure such as disaster prevention systems, smart cities, drones, and digital twin systems as part of the DX approach to municipal crisis management. What specific initiatives are they pursuing? We interviewed Hiroyuki Horii, Deputy General Manager of the Innovation Department, Corporate Strategy Division, Ando Hazama, Shigehiko Amo, Chairman of Cube Earth, and Zenshi Takeda, President and Representative Director.

Sanki Kogyo × Startups] Become a company that continues to be chosen|New Steps in Co-Creation with Startups

Sanki Kogyo Corporation, which will celebrate its 100th anniversary in 2025, has set its sights on becoming a company that will "continue to be chosen" in accordance with its vision for 2050, and is working to strengthen its core businesses and enhance the Sanki brand. One of our new initiatives is to strengthen our core business and improve the Sankiki brand. Therefore, as one of the new initiatives, we are challenging the "SANKI Open Innovation Program 2023". We interviewed Mr. Hiroyuki Sasaki, Facility Systems Business Department, Mr. Tadashi Ishiwata, Corporate Planning Department, Corporate Planning Office, and Mr. Naoya Tokuda, Corporate Planning Department, who are challenging the accelerator program for the first time, about their frank thoughts from their respective standpoints.

Ando Hazama × Air Digital × Kuki City] Tackling the challenge of extending healthy life expectancy through digital sports!

Ando Hazama, a general construction company that promotes the creation of new businesses through open innovation, has selected Air Digital Inc. Air Digital, Inc., a company involved in the development of digital sports space and the operation of digital sports fields, was selected for the program. Subsequently, Ando Hazama, Air Digital, and Kuki City, Saitama Prefecture, signed a collaboration agreement and are now working together on "Sports 60 & Smart," one of the largest digital sports clubs in Japan, which is located in the "Ario Washinomiya" shopping mall facility in Kuki City. What specific initiatives are being undertaken? We interviewed Tsubasa Sakakibara, Manager of the Innovation Department of Ando Hazama's Corporate Strategy Division, Sobaku Maeda, Representative Director of Air Digital, and Takeshi Kanazawa, a member of the Sports Promotion Section of the Health and Sports Department of the Kuki City Office.

Startup Recruitment] Caring for Community Health|Future Aisei Pharmacy with Roots in the Community through New Business

Aisei Pharmacy has more than 400 dispensing pharmacies nationwide. As the company will soon celebrate its 40th anniversary, we are challenging the accelerator program in search of the next pillar of our business! Aiming to become a pharmacy that is needed by local residents, the company will explore the possibility of creating new businesses. In this interview, we spoke with Hiroyuki Hori, General Manager of the Business Planning Department of Aisei Pharmacy Inc. about why Aisei Pharmacy is now taking on the challenge of open innovation with startups.
Facebook Comments